#Carfilzomib Market Trend | Explore Tumblr posts and blogs

priteshwemarketresearch · 4 months ago

Text

Carfilzomib Market Statistics, Segment, Trends and Forecast to 2034

TheCarfilzomib Market: Trends, Opportunities, and Future Outlook

Introduction

In recent years, the pharmaceutical industry has seen significant advancements in the treatment of multiple myeloma, a type of cancer that affects plasma cells in the bone marrow. Among these advancements, Carfilzomib has emerged as a critical player. This proteasome inhibitor, marketed under the brand name Kyprolis, has made substantial impacts in the management of multiple myeloma. In this blog, we will explore the current state of theCarfilzomib market, its growth drivers, opportunities, and future outlook.

Free Sample pdf copy:

What is Carfilzomib?

Carfilzomib is a next-generation proteasome inhibitor used in the treatment of multiple myeloma, especially in patients who have relapsed or are refractory to other therapies. Unlike its predecessor, bortezomib, Carfilzomib is known for its more selective action on the proteasome, potentially leading to fewer side effects and enhanced efficacy. Approved by the FDA in 2012, it has since become an integral part of combination therapies for multiple myeloma.

Carfilzomib Market Landscape

Growth Drivers

Rising Incidence of Multiple Myeloma: The increasing number of multiple myeloma cases globally is a significant driver for the Carfilzomib market. As the global population ages, the prevalence of multiple myeloma is expected to rise, leading to a higher demand for effective treatments.

Advancements in Treatment Protocols: Carfilzomib is often used in combination with other drugs like lenalidomide and dexamethasone, enhancing its effectiveness. This combination therapy approach has shown promising results, making Carfilzomib a preferred choice in advanced treatment regimens.

Increasing Awareness and Diagnosis: Improved diagnostic techniques and greater awareness about multiple myeloma have led to earlier detection and treatment. This trend is likely to boost the demand for Carfilzomib as part of first-line and subsequent lines of treatment.

Ongoing Clinical Trials: Continuous research and clinical trials exploring new indications and combination therapies for Carfilzomib are expanding its potential market. Studies focusing on different stages of multiple myeloma and other cancers could open new avenues for Carfilzomib use.

Carfilzomib Market Challenges

High Cost of Treatment: Carfilzomib is a high-cost drug, and its price can be a barrier to access, particularly in developing countries. The high cost of treatment may limit its market potential and lead to a preference for alternative therapies.

Side Effects and Resistance: Although Carfilzomib is well-tolerated, some patients may experience side effects such as cardiovascular issues or renal complications. Additionally, resistance to the drug can develop, leading to the need for alternative therapies.

Competition from Other Therapies: The multiple myeloma treatment landscape is competitive, with several other proteasome inhibitors and novel therapies in development. This competition can impact Carfilzomib’s market share and pricing strategies.

Market Opportunities

Expanding Indications: Research into expanding the use of Carfilzomib to other types of cancer or earlier stages of multiple myeloma could provide significant market opportunities. Successful clinical trials in these areas could lead to new indications and broaden its market.

Developing Markets: As healthcare infrastructure improves in developing regions, there ispotential for growth in these Carfilzomib Market Strategic partnerships and pricing strategies could enhance Carfilzomib’s reach in these areas.

Combination Therapies: Exploring new combination therapies and optimizing treatment regimens can improve patient outcomes and increase the demand for Carfilzomib. Collaborations with other pharmaceutical companies and research institutions could drive innovation in this space.

Carfilzomib Market Future Outlook

The Carfilzomib market is poised for continued growth driven by advancements in treatment protocols and increasing prevalence of multiple myeloma. However, challenges such as high treatment costs and competition from alternative therapies will require strategic planning and innovation.

The future of Carfilzomib will likely involve ongoing research and development to expand its therapeutic indications and improve patient outcomes. As the market evolves, stakeholders will need to navigate these dynamics to maximize the potential of Carfilzomib in the treatment of multiple myeloma and beyond.

Conclusion

Carfilzomib Market has made asignificant impact in the management of multiple myeloma, and its market prospects remain strong. With ongoing advancements in treatment protocols, increasing awareness, and expanding indications, Carfilzomib is set to continue playing a crucial role in cancer therapy. However, addressing market challenges and seizing emerging opportunities will be essential for stakeholders to fully realize the potential of this innovative drug.

#Carfilzomib Market Share #Carfilzomib Market Demand #Carfilzomib Market Scope #Carfilzomib Market Analysis #Carfilzomib Market Trend

0 notes

jean-perry · 2 years ago

Text

0 notes

cainemily98 · 3 years ago

Link

0 notes

karishmamulani · 4 years ago

Text

Blood Cancer Drugs Market Size, Share, Trends and Future Analysis by PMR

The global blood cancer drugs market is anticipated to reach USD 55.6 billion by 2025 according to a new report published by Polaris Market Research. The report ‘Blood Cancer Drugs Market [By Blood Cancer Type (Leukemia (Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia), Lymphoma (Hodgkin Lymphoma, Non-Hodgkin Lymphoma (B-Cell Lymphoma, T-Cell Lymphoma)), and Myeloma; By Drugs (Rituaxan/Mabthera (Rituximab), Gleevac/Glivec (Imatinib), Revlimid (Lenalidomide), Velcade (Bortezomib), Tasigna (Nilotinib), Pomalyst (Pomalidomide), Vidaza (Azacitidine), Kyprolis (Carfilzomib), Adcetris (Brentuximab Vedotin), and Others); By Treatment Approaches (Chemotherapeutic, mAbs/Targeted Therapies, and Immunotherapeutic); By Region]: Market Size & Forecast, 2017 – 2025’ provides insights on the current market scenario and the future prospects.

The demand for blood cancer drug is primarily driven by growing death incidences by blood cancer, and continuous innovation for developing novel treatments with the help of several ongoing clinical trials. Moreover, increasing research and development of biological and targeted therapies as treatment will spur the blood cancer drugs market during the upcoming period. However, the high price of drugs and the stringent government policies will limit the growth of blood cancer drugs market during the forecast period.

Most of the blood cancers start in the bone marrow, where blood is produced. In blood cancer the growth of normal blood cells is dislodged by the uncontrollable growth of abnormal blood cells. These cancerous cells prevent the blood from performing many of its functions. Hence, the existing treatments of blood cancer are being the foundation for developing the new drugs. The steady flow of the blood cancer drugs has created opportunity for research and development in the existing market. For instance, Amgen Inc. received approval for BLINCYTO in July 2017, which is used in treating B-cell precursor Acute Lymphoblastic leukemia. Similarly, European blood cancer drugs market witnessed the approvals of Gazyvaro, by Roche AG that is used in treating advanced follicular lymphoma. Also, novel technologies like CAR-T are likely to be launched this year.

Download Sample copy : https://www.polarismarketresearch.com/industry-analysis/global-blood-cancer-drugs-market/request-for-sample

The global blood cancer drugs market is segmented into blood cancer type, drugs and treatment approaches. On the basis of blood cancer type, the global blood cancer drugs market is segmented into leukemia, lymphoma and myeloma. The lymphoma segment is expected to drive the majority market of blood cancer drugs followed by leukemia. The global market of this segment is primarily driven by the increasing prevalence of lymphoma, and presence of effective treatments in the market. On the basis of drugs, the global blood cancer drugs market is further categorized into Rituaxan/Mabthera (Rituximab), Gleevac/Glivec (Imatinib), Revlimid (Lenalidomide), Velcade (Bortezomib), Tasigna (Nilotinib), Pomalyst (Pomalidomide), Vidaza (Azacitidine), Kyprolis (Carfilzomib), Adcetris (Brentuximab Vedotin), and Others. This continuous innovation for treating various sub-types of blood cancers has led to the development of novel types of treatments. For instance, the combination of Revlimid and Velcade has emerged as the preferential drugs in trials for treating multiple myeloma.

On the basis of treatment approaches the global blood cancer drugs market is further segmented into Chemotherapeutic, mAbs/Targeted Therapies, and Immunotherapeutic. Due to availability of variety of chemotherapeutic agent in the market chemotherapeutic drugs are expected to hold the higher share in blood cancer drugs market. Moreover, their effectiveness for the treatment of blood cancer and increasing number of cancer patients globally has garnered more demand for chemotherapeutic drugs throughout the world.

Geographically, the global blood cancer drugs market is segmented into North America, Europe, Asia Pacific, and the rest of the world. North America dominates the blood cancer drugs market which is followed by Europe and Asia Pacific. Favorable reimbursement policies, surge in R&D investments of various companies, as well as the increase in the number of blood cancer treatments are some of the major factors responsible for the growth of North America’s blood cancer drugs market. Moreover, Asia-Pacific region has been identified as the lucrative market for the for blood cancer drugs due to increasing awareness of the use of these drugs, increased healthcare expenditure, and rising per capita disposable income. These are some of the major factors which are influencing the growth of the blood cancer drugs in Asia-pacific region.

Have Questions? make an Inquiry before buying this report by clicking the link below: https://www.polarismarketresearch.com/industry-analysis/global-blood-cancer-drugs-market/request-for-discount-pricing

The leading companies operating in this industry include Johnson & Johnson Inc., Amgen Inc., Bayer AG., Pfizer, Inc., AbbVie Inc., Roche Holding AG., Celgene Corporation, AstraZeneca, Novartis AG, GlaxoSmithKline PLC, Merck & Co., Inc., and Eli Lily & Co. among others.

Key Findings from the study suggest blood cancer drugs in the market are much innovative and manufacturers are progressively concentrating on innovation of combination drugs. Companies are in a stage of development of new drugs in order to provide novel treatments for blood cancer. The immunotherapy segment is anticipated to grow at a high growth rate over the forecast period. The growth of this segment is primarily driven by increased awareness for its use as an alternative and effective treatment for blood cancer. North America is presumed to dominate the global blood cancer drugs market over the forecast period. Asia Pacific region which shows signs of high growth potential owing to the booming economies of India, and China.

#Blood Cancer Drugs Market

0 notes

rdagade · 4 years ago

Text

Global Multiple Myeloma Treatment Market

Global Multiple Myeloma Treatment Market size was valued US$ XX Mn. in 2019 and the total revenue is expected to grow at 11.34% from 2019 to 2027, reaching nearly US$ XX Mn.

Global Multiple Myeloma Treatment Market

The report study has analyzed the revenue impact of COVID -19 pandemic on the sales revenue of market leaders, market followers, and market disrupters in the report, and the same is reflected in our analysis.

Multiple myeloma, also known as Kahler’s disease, is a type of blood cancer of plasma cells that are found in the bone marrow. Multiple myeloma causes cancer cells to accrue in the bone marrow, where they attack the strong blood cells.

Multiple myeloma treatments have developed significantly above the last decade. New multiple myeloma treatments have provided efficient survival rates between myeloma patients. It has been also observed that the future drug pipeline of multiple myeloma is promising, biological drugs and stem cell-based therapies are likely to fuel the multiple myeloma treatment market in the upcoming years. On the other hand, the costs of radiotherapeutic equipment implementation, a limited number of target patient’s population, strict legal regulations are expected to hamper the market growth. Likewise, the MMR report contains a detailed study of factors that will drive and restrain the growth of the multiple myeloma treatment market globally.

Multiple Myeloma accounts for approximately 2.5% of the cancer-related deaths globally and is the second most major type of blood cancer next to Hodgkin’s Lymphoma. According to the World Cancer Research Fund, in 2018, above 159500 cases of multiple myeloma were diagnosed with the condition, where the occurrence rate among women and men was found in the ratio 1.2:1. The onset of the disease occurs after the age of 60. In recent times, the age of onset is drastically decreasing. In the year 2001, only two medications were available for treating multiple myeloma but now in 2020, 18 medicines are available. Moreover, there are over 25 FDA-approved drugs for treating multiple myeloma with therapeutics such as pomalidomide, carfilzomib, panobinostat, and ixazomib. The availability of new medications has given new hope for better treatments and better results and thus affecting the growth of the market as well. However, the survival of patients with a limited response while receiving treatment with primary immunodeficiency therapy remains poor and is one of the major challenges.

The MMR report covers the segments in the multiple myeloma treatment market such as type and application. By application, the hospital is expected to continue to hold the largest XX.85% share in multiple myeloma treatments market thanks to growing specialist doctors providing the best chance of long term survival.

North America’s multiple myeloma treatments market was valued at US$ XX.26 Mn. in 2019 and is expected to reach a value of US$ XX.13 Mn. by 2027, with a CAGR of 9.3%. The number of patients in the U.S is growing YoY with nearly 14600 new cases diagnosed annually. In 2017 alone there were approximately 142000 patients diagnosed for multiple myeloma.

Europe and the South African population are prone to develop multiple myeloma when compared with Asian economies. Though, the population in the APAC region outwits Europe and Africa. Further, growing the adoption rate of novel therapies, coupled with the support from the government along with non-government organizations and improving the survival of multiple myeloma patients.

The research study includes the profiles of leading players operating in the global multiple myeloma treatment market. Eli Lilly Company acquired ARMO Biosciences to develop immunotherapies for the treatment of cancer, hypercholesterolemia, inflammatory, and fibrosis diseases.

The objective of the report is to present a comprehensive analysis of the Global Multiple Myeloma Treatment Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that includes market leaders, followers, and new entrants. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors of the market has been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers. The report also helps in understanding Global Multiple Myeloma Treatment Market dynamics, structure by analyzing the market segments and projects the Global Multiple Myeloma Treatment Market size. Clear representation of competitive analysis of key players by Application, price, financial position, Product portfolio, growth strategies, and regional presence in the Global Multiple Myeloma Treatment Market make the report investor’s guide.

For more information visit@ https://www.maximizemarketresearch.com/market-report/global-multiple-myeloma-treatment-market/65671/

Scope of the Global Multiple Myeloma Treatment Market

Global Multiple Myeloma Treatment Market, by Applications

• Hospitals • Clinics • Cancer Treatment and Rehabilitation Centers Global Multiple Myeloma Treatment Market, by Type

• Proteasome Inhibitors • Immunomodulatory Agents (IMiDs) • Histone Deacetylase (HDAC) Inhibitors • Immunotherapy • Cytotoxic Chemotherapy Global Multiple Myeloma Treatment Market, by Region

• Asia Pacific • North America • Europe • South America • Middle East & Africa Key players operating in Global Multiple Myeloma Treatment Market

• Celgene Corporation • Janssen Biotech, Inc. • Bristol-Myers Squibb Company • Novartis AG • Cellectar Biosciences Inc. • Millennium Pharmaceuticals • Amgen, Inc. • bbVie • Genzyme Corporation • Juno Therapeutics • Eli Lilly and Company • Glenmark Pharma

This report submitted by Maximize market Research Company

Customization of the report:

Maximize Market Research provides free personalized of reports as per your demand. This report can be personalized to meet your requirements. Get in touch with us and our sales team will guarantee provide you to get a report that suits your necessities.

About Maximize Market Research:

Maximize Market Research provides B2B and B2C research on 20,000 high growth emerging opportunities & technologies as well as threats to the companies across the Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.

Contact info:

Name: Lumawant Godage

Organization Address: MAXIMIZE MARKET RESEARCH PVT. LTD.

Email: [email protected]

Address: Omkar Heights, Sinhagad Road, Manik Baug, Vadgaon Bk,Pune, Maharashtra 411051, India.

Contact: +919607195908

#Global Multiple Myeloma Treatment Market

0 notes

hello-delveinsight · 4 years ago

Text

Multiple Myeloma Market Size Forecast, Epidemiology Analysis, Emerging Drug Uptake and Key Companies Assessment by DelveInsight

(LAS VEGAS, US) The Multiple Myeloma Market size across the 8MM i.e. the United States, Eu5(the UK, Germany, France, Italy, Spain), China and Japan, was $16.27bn in 2019 and is increasing with a modest CAGR during the study period (2017-2030), according to DelveInsight, a leading company in healthcare analytics and consulting.

The market size for Multiple Myeloma therapies will increase dramatically by 2030 due to the arrival of upcoming therapies that will carve out niche roles in the drug landscape. DelveInsight's latest report on Multiple Myeloma Epidemiology and Market indicates that the impressive growth in market size is due to the rise in incident cases of Multiple Myeloma in 8MM, incorporation of immune-therapies in treatment landscape increased patient adherence and adoption of newer therapies. Also, rich emerging pipeline, better diagnosis, rising awareness and expected increase in investment in the R&D activities are some additional factors that are going to fuel the market.

Some key highlights from the report:

The total incident cases of Multiple Myeloma are expected to reach 91,520 in 2020 in the 8MM

Higher usage of bortezomib based regimen observed across the US, EU5 and JP; Bortezomib + Lenalidomide + dex regimen is the preferred treatment choice in the US and Japan in the first-line compared to Bortezomib + Melphalan ± Prednisone and Bortezomib + dex regimen in EU5. In the case of China, higher usage of thalidomide based regimen found in the first-line setting

Among emerging therapies, Bristol Myers Squibb and Bluebird Bio's anti-BCMA CAR T Cell Therapy Idecabtagene Vicleucel (Ide-cel, bb2121) is expected to result in significant revenues owing to promising results, one-time dosing and premium pricing in heavily pretreated patients

Key Companies fuelling the Multiple Myeloma market size growth are GlaxoSmithKline, Bristol-Myers Squibb, AbbVie, Roche, Janssen Research & Development, Merck Sharp & Dohme Corp., Pfizer, Takeda, Amgen, AstraZeneca etc.

Patent expiry of multiple blockbuster drugs like Revlimid, Pomalyst, Darzalex and Kyprolis is on the lines to expire from 2026 onwards, and this will erode the sales value significantly and the market is expected to decline from 2028 onwards due to cumulative impacts of patent expiry.

Download Multiple Myeloma Sample: https://www.delveinsight.com/sample-request/multiple-myeloma-market

Though Multiple Myeloma is not common cancer; still, it is the second most diagnosed blood cancer in the United States. It is worth highlighting that it is a heterogeneous haematological malignancy in which epidemiology plays an increasingly important role. Over the past years, intensive clinical and molecular epidemiological research has extended the information about its pathogenesis, risk factors, and prognostic components which aided the approval of new drugs. Despite arduous research endeavors, the etiology remains enigmatic. The untimely or prolonged diagnosis has a severe impact on the clinical course of Multiple myeloma and a negative impact on disease-free survival. It's an unfortunate fact that approximately 95% of all the Multiple Myeloma cases are diagnosed at distant stages. The report reviews the changing epidemiology and provides the forecasts upto 2030, highlights treatment patterns, and the health disparity observed in important subgroups of Multiple Myeloma.

Multiple myeloma report contains epidemiological analysis segmented as the following:

Total Multiple Myeloma Incident Cases

Total Multiple Myeloma Incident cases by Age Distribution

Total Symptomatic Multiple Myeloma Cases

Cases of Multiple Myeloma by Treatment Line

Gender-specific cases of Multiple Myeloma

Multiple Myeloma Market Scenario

The current standard of care of Multiple myeloma treatment includes stem cell transplant, conventional chemotherapy, targeted therapy, surgery, and radiation therapy. Chemotherapies can be given alone or in conjunction with other drugs including corticosteroids, proteasome inhibitors, immune-modulators, and monoclonal antibodies, anti-resorptive agents such as bisphosphonates and NSAIDs, or narcotics. Currently, Lenalidomide is the market leader in multiple myeloma treatment landscape, and usage as monotherapy and also in combination with other therapies can be found across all the settings. Darzalex is also being used by the healthcare experts in combination as doublet, triplet, and quadruplet with existing therapies for the good treatment strategies and better result outcomes and has impacted the MM treatment landscape significantly. Label expansion along with higher usage of Darzalex has translated into higher revenues and expected to generate maximum revenue by 2025 before the competition and expected patent expiry would erode the sales value. At present, among the IMid's agents, Revlimid dominates the Multiple Myeloma market in the 8MM, where it is included in all lines of Multiple Myeloma therapy either as monotherapy or in combination with other drugs. In 2017, Revlimid generated a revenue of USD 7,140 million in the 8MM. Despite the loss of patent exclusivity among the major markets and approval of other potential pipeline candidates, it will continue to maintain a strong presence during the forecast period as a molecule. The novel emerging therapies are expected to bring a paradigm shift in the Multiple Myeloma treatment landscape by catering to larger unmet needs.

Report includes exhaustive analysis of Multiple Myeloma Pipeline Therapies

Idecabtagene vicleucel (ide-cel): Bristol Myers Squibb and bluebird bio

Venetoclax (Venclexta, Venclyxto): AbbVie

JNJ-68284528 LCAR-B38M/JNJ-4528): Janssen Research and Development

Keytruda (pembrolizumab): Novartis

Melflufen (melphalan flufenamide): Oncopeptides

Cetrelimab (JNJ-63723283): Janssen Research and Development

REGN5458: Regeneron Pharmaceuticals

Iberdomide: Celgene

NY-ESO-1 C259 T Cells: GlaxoSmithKline

Braftovi (encorafenib): Pfizer

JCARH125: Celgene Corporation

Felzartamab (MOR202): I-Mab Biopharma

Chidamide (Epidaza): Shenzhen Chipscreen Bioscience

The past couple of decades have shown vast changes in the treatment landscape of Multiple Myeloma, starting with the use of stem cells trailed by the availability of novel treatments such as immunomodulators and proteasome inhibitors that have transformed the natural history of the indication, leading to increased survival times. Ongoing advancements in emerging Novel therapies such as CAR-T cell and monoclonal antibodies are showing promising results in treating multiple myeloma patients and are also expected to drive the growth of the market. Recent years have witnessed an influx of several pharma companies exploring the Multiple Myeloma market through novel targets and therapies. Although the emerging pipeline candidates will reduce the gaps however, the opportunities will still remain. As a ray of hope, the launch of new drugs have extended the median overall survival of Multiple Myeloma patients to 4-6 years; however the stark reality is that the ten year survival rate is 3%. The long term burden of the therapies makes life pretty difficult for the patients. There is a dire need for a permanent cure. Another hurdle is the existing expensive treatment options that create a barrier for the aged uninsured population to get hold of costly therapies. The factors like drug-induced toxicities, differences in clinical care, access to the therapies in real-world settings are the observed gaps between trial-based and real-world outcomes. DelveInsight believes that the Multiple Myeloma market is an attractive prospect for the companies due to the high unmet needs and low regulatory hurdles.

Key Trends of Multiple Myeloma Market Report: https://www.delveinsight.com/report-store/multiple-myeloma-market

Scope of the Report

Geography Covered: 8MM - The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan, and Chine.

Study Period: 3-year historical and 11-year forecasted analysis (2017-2030).

Markets Segmentation: By Geographies, By Therapies (Forecasted + Historical).

Companies Covered: GlaxoSmithKline, Bristol-Myers Squibb, AbbVie, Roche, Janssen Research & Development, Merck Sharp & Dohme Corp., Pfizer, Takeda, Amgen, AstraZeneca, and several others.

Analysis: Comparative and conjoint analysis of emerging therapies, Attribute Analysis,

Case Studies

KOL's Views

Analyst's View

The Multiple Myeloma Marketed drugs covered report are:

Sarclisa (Isatuximab): Sanofi

Darzalex (Daratumumab): Janssen Research and Development

Empliciti (Elotuzumab): Bristol-Myers Squibb and AbbVie

Velcade (bortezomib): Takeda

Pomalyst (Pomalidomide): Celgene Corporation

Revlimid (Lenalidomide): Celgene Corporation

Farydak (panobinostat): Novartis Pharmaceuticals

Kyprolis (Carfilzomib): Amgen

Ninlaro (ixazomib): Takeda Pharmaceuticals

Blenrep (Belantamab Mafodotin): GlaxoSmithKline

Table of Contents

Key Insights

Executive Summary of Multiple Myeloma

KOL Views

SWOT Analysis of Multiple Myeloma

Multiple Myeloma Market Overview at a Glance

Disease Background and Overview: Multiple Myeloma

Diagnosis of Multiple Myeloma

Multiple Myeloma Epidemiology and Patient Population

The United States Multiple Myeloma Epidemiology

EU-5 Multiple Myeloma Epidemiology

Japan Multiple Myeloma Epidemiology

China Multiple Myeloma Epidemiology

Multiple Myeloma Treatment

Unmet Needs in the Multiple Myeloma Market

Patient Journey of Multiple Myeloma

Key Endpoints of Multiple Myeloma Clinical Trials

Multiple Myeloma Marketed Therapies

Multiple Myeloma Emerging Therapies

Multiple Myeloma 8 Major Market Analysis

8MM Multiple Myeloma Market Size

The United States Multiple Myeloma Market Size

EU-5 Multiple Myeloma Market Size

Japan Multiple Myeloma Market Size

China Multiple Myeloma Market Size

Market Access and Reimbursement of Multiple Myeloma (MM) Therapies

Multiple Myeloma Market Drivers

Multiple Myeloma Market Barriers

Appendix

DelveInsight Capabilities

Disclaimer

About DelveInsight

Request a WebEx Walkthrough of the Report: https://www.delveinsight.com/report-store/multiple-myeloma-market

Related Report:

CAR T-Cell Therapy for Multiple Myeloma-Market Insights and Market Forecast-2030 : This report delivers an in-depth understanding of the CAR T-Cell Therapy use for Multiple Myeloma as well as the CAR T-Cell Therapy market trends for Multiple Myeloma. It provides current treatment practices, emerging drugs, CAR T-Cell Therapy market share of the various CAR T-Cell Therapies for Multiple Myeloma, the individual therapies, current and forecasted Multiple Myeloma CAR T-Cell Therapy market Size from 2017 to 2030.

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end to end comprehensive solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

SOURCE DelveInsight Business Research, LLP

0 notes

aleemtbrc · 5 years ago

Text

Western Europe Blood Cancer Drugs Market Trends And Strategies 2022

A report from TheBusinessResearchCompany shows that the "Global Blood Cancer Drugs Market 2019" is expected to grow to $43.74 billion at a CAGR of 7.3% through 2022.

The Business Research Company’s Blood Cancer Drugs Global Market Report 2019 covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

Explore Complete Report “Blood Cancer Drugs Global Market 2019” at https://www.thebusinessresearchcompany.com/report/blood-cancer-drugs-global-market-report

Ratios of market size and growth to related markets, GDP proportions, and expenditure per capita for the market is detailed in the report. Data and analysis throughout the report is sourced using end notes.

The global blood cancer drugs market was valued at about $33 billion in 2018 and is expected to grow to $43.74 billion at a CAGR of 7.3% through 2022.

Major Key competitive players in the global Blood Cancer Drugs market report include Amgen Inc., AstraZeneca PLC, Bayer AG, Celgene Corporation, Eli Lilly.

The blood cancer drugs market is a segment of the pharmaceuticals market. The report will answer questions such as where the largest and fastest growing market is, how the market relates to the overall economy, demography and other similar markets, and what forces will shape the market going forward.

Request to get the sample of this report https://www.thebusinessresearchcompany.com/sample.aspx?id=2587&type=smp

The blood cancer drugs market consists of sales of drugs to treat all types of blood cancers. The blood cancer drugs market excludes biologics and includes establishments that produce drugs used in chemotherapy, surgery and radio therapies for treating leukemia, lymphoma, and myeloma. The blood cancer drugs include Rituaxan/Mabthera (Rituximab), Gleevac/Glivec (Imatinib), Revlimid (Lenalidomide), Velcade (Bortezomib), Tasigna (Nilotinib), Pomalyst (Pomalidomide), Vidaza (Azacitidine), Kyprolis (Carfilzomib), Adcetris (Brentuximab Vedotin) and others.

List of Tables from the Report:

Table 1: Global Historic Market Growth, 2014-2018, $ Billion

Table 2: Global Forecast Market Growth, 2014-2022F, 2025F, 2030F, $ Billion

Table 3: Global Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

Table 4: Global Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

Table 5: Global Blood Cancer Drugs Market, Split By Region, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

Table 6: Global Blood Cancer Drugs Market, Split By Country, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

Table 44: Africa, Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

Table 45: Amgen Inc. Financial Performance

Table 46: AstraZeneca PLC Financial Performance

Table 47: Bayer AG Financial Performance

Table 48: Celgene Corporation Financial Performance

Table 49: Eli Lilly Financial Performance

For latest press releases visit https://www.thebusinessresearchcompany.com/press-release.aspx

About Us:

The Business Research Company is a Business Intelligence Company which excels in company, market and consumer research. It has offices in the UK, the US and India and a network of trained researchers in 15 countries globally.

Contact Information:

The Business Research Company

Europe: +44 207 1930 708

Asia: +91 8897263534

Americas: +1 315 623 0293

Email: [email protected]

#blood cancer drugs market #blood cancer drugs market growth #blood cancer drugs market companies #blood cancer treatment #blood cancer approved drugs

0 notes

healthcarepharma-blog · 7 years ago

Text

Global Carfilzomib Market Professional Survey Trends by Product and Application 2017

Festive Month Offer -

20% discount on purchase of reports from 1st October to 31st October.

https://www.researchtrades.com/discount/1274651

For more offers post 31st October, kindly contact us. * Terms & Conditions apply!!

Contact No. : +16269994607 (US), /+91 7507349866 (IND)

Email: [email protected]

Report Overview:

The “Global Carfilzomib Market Research Report” is a professional and in-depth study on the current state of the Carfilzomib Market. The study offers an insight into current and future market trends, key drivers and restraints, market strategies of key market players along with detailed segmentation and forecast. The study offers industry overview by covering basic aspects such as product definition and classification, market size and share of segments and sub-segments. This report offers market insights into the changing dynamics by analysis the elements of industry chain structure, key marketing channels and the innovative strategies adopted by key market players to gain a competitive advantage in the market.

Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Carfilzomib in these regions, from 2012 to 2022 (forecast), covering

North America

Europe

China

Japan

Southeast Asia

India

Get Exclusive sample copy @ https://www.researchtrades.com/request-sample/1274651

Global Carfilzomib market competition by top manufacturers, with production, price, revenue (value) and market share for each manufacturer; the top players including

Cayman Chemical

Tecoland Corporation

Gyma Laboratories of America, Inc

Vijayasri Organics Limited

Active Peptide

Shanghai Chiral Chemicals

Amgen Inc

On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into

Type I

Type II

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, consumption (sales), market share and growth rate of Carfilzomib for each application, including

Anti-Cancer

Others

Table of Contents

1 Carfilzomib Market Overview

1.1 Product Overview and Scope of Carfilzomib

1.2 Carfilzomib Segment by Type (Product Category)

1.2.1 Global Carfilzomib Production and CAGR (%) Comparison by Type (Product Category)(2012-2022)

1.2.2 Global Carfilzomib Production Market Share by Type (Product Category) in 2016

1.2.3 Type I

1.2.4 Type II

1.3 Global Carfilzomib Segment by Application

2 Global Carfilzomib Market Competition by Manufacturers

2.1 Global Carfilzomib Capacity, Production and Share by Manufacturers (2012-2017)

2.1.1 Global Carfilzomib Capacity and Share by Manufacturers (2012-2017)

2.1.2 Global Carfilzomib Production and Share by Manufacturers (2012-2017)

2.2 Global Carfilzomib Revenue and Share by Manufacturers (2012-2017)

2.3 Global Carfilzomib Average Price by Manufacturers (2012-2017)

2.4 Manufacturers Carfilzomib Manufacturing Base Distribution, Sales Area and Product Type

….

Browse This Report @ https://www.researchtrades.com/report/global-carfilzomib-market-research-report-2017/1274651

Who we are

Research Trades has team of experts who works on providing exhaustive analysis pertaining to market research on a global basis. This comprehensive analysis is obtained by a thorough research and study of the ongoing trends and provides predictive data regarding the future estimations, which can be utilized by various organizations for growth purposes.

#Global Carfilzomib Market Share #Global Carfilzomib Market Trends #Global Carfilzomib Market Analysis #Research Trades

0 notes

priteshwemarketresearch · 2 days ago

Text

0 notes

cainemily98 · 3 years ago

Link

0 notes

deafeningmusicfury · 5 years ago

Text

Blood Cancer Drugs Market Latest Trends & Future Opportunities 2026

Request for a sample copy of this research report @ https://www.polarismarketresearch.com/industry-analysis/global-blood-cancer-drugs-market/request-for-sample

Complete Summary with TOC Available @ https://www.polarismarketresearch.com/industry-analysis/global-blood-cancer-drugs-market

Polaris Market Research has segmented the global blood cancer drugs market on the basis of type, drugs, treatment approaches and region:

Blood cancer drugs market Size and Forecast, 2017-2025 by Drugs

Rituaxan/Mabthera (Rituximab)

Gleevac/Glivec (Imatinib)

Revlimid (Lenalidomide)

Velcade (Bortezomib)

Tasigna (Nilotinib)

Pomalyst (Pomalidomide)

Vidaza (Azacitidine)

Kyprolis (Carfilzomib)

Adcetris (Brentuximab Vedotin)

Others

Blood cancer drugs market Size and Forecast, 2017-2025 by Treatment Approaches

Chemotherapeutic

mAbs/Targeted Therapies

Immunotherapeutic

Blood cancer drugs market Size and Forecast, 2017-2025 by Region

U.S.

Canada

Germany

France

China

Japan

India

Brazil

Mexico

Purchase This Report @: https://www.polarismarketresearch.com/checkouts/2071

About Polaris Market Research

Polaris Market Research is a global market research and consulting company. The company specializes in providing exceptional market intelligence and in-depth business research services for our clientele spread across different enterprises.

Polaris Market Research

Phone: 1–646–568–9980

Email: [email protected]

Web: www.polarismarketresearch.com

#Blood Cancer Drugs Market #Blood Cancer Drugs Market share #Blood Cancer Drugs Market size

0 notes

abrreports-blog · 5 years ago

Text

Carfilzomib Market Key Trends, Drivers, Growth Opportunities, and 2025 Industry Chain Structure Analysis

The research study Carfilzomib market 2020 launched by ABRReports.com provides the detailed analysis of current market status, investment plans, production and consumption, price trends, leading key companies, growth drivers and future prospect. The base year considered for the study is 2019, and the market size is projected from 2020 to 2025

Get the Sample Copy of Carfilzomib market report at https://www.abrreports.com/industry-insights/2020-2025-global-and-regional-carfilzomib-industry-production-sales-and-consumption-status-and-prospects-professional-market-research-report?form=request-report-sample

The segmentation of Carfilzomib study as mentioned below:

By Market Players:

Amgen, Natco, AstraZeneca

By Application

Hospital, Clinic, Drug Center, Other10mg Injection, 30mg Injection, 60mg Injection

The points that are discussed within the report are the major market players that are involved in the market such as manufacturers, raw material suppliers, equipment suppliers, end users, traders, distributors and etc. The complete profile of the companies is mentioned. And the capacity, production, price, revenue, cost, gross, gross margin, sales volume, sales revenue, consumption, growth rate, import, export, supply, future strategies, and the technological developments that they are making are also included within the report. The historical data from 2014 to 2019 and forecast data from 2020 to 2025.

The growth factors of the market are discussed in detail wherein the different end users of the market are explained in detail. Data and information by manufacturer, by region, by type, by application and etc, and custom research can be added according to specific requirements. The report contains the SWOT analysis of the market. Finally, the report contains the conclusion part where the opinions of the industrial experts are included.

Click to access full report and Table of Content at https://www.abrreports.com/industry-insights/2020-2025-global-and-regional-carfilzomib-industry-production-sales-and-consumption-status-and-prospects-professional-market-research-report

The key objective of this report is to help the user understand the market in terms of its definition, segmentation, market potential, influential trends, and the challenges that the market is facing. Deep researches and analysis were done during the preparation of the report. The readers will find this report very helpful in understanding the market in depth. The data and the information regarding the market are taken from reliable sources such as websites, annual reports of the companies, journals, and others and were checked and validated by the industry experts. The facts and data are represented in the report using diagrams, graphs, pie charts, and other pictorial representations. This enhances the visual representation and also helps in understanding the facts much better.

Purchase the research study @ https://www.abrreports.com/industry-insights/2020-2025-global-and-regional-carfilzomib-industry-production-sales-and-consumption-status-and-prospects-professional-market-research-report/checkout?option=one

Key pointers of the Table of Contents:

Chapter 1 Industry Overview

Chapter 2 Major Segmentation (Classification, Application and etc.) Analysis

Chapter 3 Production Market Analysis

Chapter 4 Sales Market Analysis

Chapter 5 Consumption Market Analysis

Chapter 6 Production, Sales and Consumption Market Comparison Analysis

Chapter 7 Major Manufacturers Production and Sales Market Comparison Analysis

Chapter 8 Marketing Channel Analysis

Chapter 9 Industry Chain Analysis

Chapter 10 Global and Regional Market Forecast

Chapter 11 Major Manufacturers Analysis

Chapter 12 New Project Investment Feasibility Analysis

Chapter 13 Conclusions

Continued…

About Us:

ABR Reports (Advanced Business Research Reports) is the premium market research reselling company which offers market research reports to individuals, organizations and industries to enhance and strengthen the decision making process. With associate thoroughgoing list of market research Publishers we tend to cut across over all the business verticals covering 5000+ micro markets and offer market size and share analysis, industry trend, information on products, regional market and keen business insights to our clients.

Scott Harris

Sales Manager

Email ID: [email protected]

Phone No.: +1-561-448-7424

#Carfilzomib market analysis #Carfilzomib market price #Carfilzomib market demand #Carfilzomib market production

0 notes

rdagade · 4 years ago

Text

Global Multiple Myeloma Treatment Market

Global Multiple Myeloma Treatment Market size was valued US$ XX Mn. in 2019 and the total revenue is expected to grow at 11.34% from 2019 to 2027, reaching nearly US$ XX Mn. The report study has analyzed the revenue impact of COVID -19 pandemic on the sales revenue of market leaders, market followers, and market disrupters in the report, and the same is reflected in our analysis. Multiple myeloma, also known as Kahler’s disease, is a type of blood cancer of plasma cells that are found in the bone marrow.

Multiple myeloma causes cancer cells to accrue in the bone marrow, where they attack the strong blood cells. Multiple myeloma treatments have developed significantly above the last decade. New multiple myeloma treatments have provided efficient survival rates between myeloma patients.

It has been also observed that the future drug pipeline of multiple myeloma is promising, biological drugs and stem cell-based therapies are likely to fuel the multiple myeloma treatment market in the upcoming years. On the other hand, the costs of radiotherapeutic equipment implementation, a limited number of target patient’s population, strict legal regulations are expected to hamper the market growth. Likewise, the MMR report contains a detailed study of factors that will drive and restrain the growth of the multiple myeloma treatment market globally. Multiple Myeloma accounts for approximately 2.5% of the cancer-related deaths globally and is the second most major type of blood cancer next to Hodgkin’s Lymphoma.

According to the World Cancer Research Fund, in 2018, above 159500 cases of multiple myeloma were diagnosed with the condition, where the occurrence rate among women and men was found in the ratio 1.2:1. The onset of the disease occurs after the age of 60. In recent times, the age of onset is drastically decreasing. In the year 2001, only two medications were available for treating multiple myeloma but now in 2020, 18 medicines are available. Moreover, there are over 25 FDA-approved drugs for treating multiple myeloma with therapeutics such as pomalidomide, carfilzomib, panobinostat, and ixazomib.

The availability of new medications has given new hope for better treatments and better results and thus affecting the growth of the market as well. However, the survival of patients with a limited response while receiving treatment with primary immunodeficiency therapy remains poor and is one of the major challenges. The MMR report covers the segments in the multiple myeloma treatment market such as type and application. By application, the hospital is expected to continue to hold the largest XX.85% share in multiple myeloma treatments market thanks to growing specialist doctors providing the best chance of long term survival. North America’s multiple myeloma treatments market was valued at US$ XX.26 Mn. in 2019 and is expected to reach a value of US$ XX.13 Mn. by 2027, with a CAGR of 9.3%.

The number of patients in the U.S is growing YoY with nearly 14600 new cases diagnosed annually. In 2017 alone there were approximately 142000 patients diagnosed for multiple myeloma. Europe and the South African population are prone to develop multiple myeloma when compared with Asian economies. Though, the population in the APAC region outwits Europe and Africa. Further, growing the adoption rate of novel therapies, coupled with the support from the government along with non-government organizations and improving the survival of multiple myeloma patients. The research study includes the profiles of leading players operating in the global multiple myeloma treatment market.

Eli Lilly Company acquired ARMO Biosciences to develop immunotherapies for the treatment of cancer, hypercholesterolemia, inflammatory, and fibrosis diseases. The objective of the report is to present a comprehensive analysis of the Global Multiple Myeloma Treatment Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that includes market leaders, followers, and new entrants.

PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors of the market has been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers. The report also helps in understanding Global Multiple Myeloma Treatment Market dynamics, structure by analyzing the market segments and projects the Global Multiple Myeloma Treatment Market size. Clear representation of competitive analysis of key players by Application, price, financial position, Product portfolio, growth strategies, and regional presence in the Global Multiple Myeloma Treatment Market make the report investor’s guide.

For more information visit@ https://www.maximizemarketresearch.com/market-report/global-multiple-myeloma-treatment-market/65671/

Scope of the Global Multiple Myeloma Treatment Market

Global Multiple Myeloma Treatment Market, by Applications

• Hospitals • Clinics • Cancer Treatment and Rehabilitation Centers

Global Multiple Myeloma Treatment Market, by Type

• Proteasome Inhibitors • Immunomodulatory Agents (IMiDs) • Histone Deacetylase (HDAC) Inhibitors • Immunotherapy • Cytotoxic Chemotherapy

Global Multiple Myeloma Treatment Market, by Region

• Asia Pacific • North America • Europe • South America • Middle East & Africa

Key players operating in Global Multiple Myeloma Treatment Market

This report submitted by Maximize market Research Company

Customization of the report:

About Maximize Market Research:

Contact info:

Name: Lumawant Godage

Organization Address: MAXIMIZE MARKET RESEARCH PVT. LTD.

Email: [email protected]

Address: Omkar Heights, Sinhagad Road, Manik Baug, Vadgaon Bk,Pune, Maharashtra 411051, India.

Contact: +919607195908

#Global Multiple Myeloma Treatment Market

0 notes

crystalmarketresearch · 5 years ago

Text

Carfilzomib Market - Global Industry Analysis & Forecast to 2025

Carfilzomib Market – Global Industry Analysis & Forecast to 2025

Crystal Market Research Offers A new market research report on Global Carfilzomib Market 2025 is expected to show tremendous growth in the coming years.

Analysts also analyzed the ongoing trends in Carfilzomib Market and the opportunities for growth in the industries up to 2025. It likewise examines Carfilzomib Industry scope, potential, benefit which significantly studies Industry execution at a…

View On WordPress

0 notes

priteshwemarketresearch · 4 months ago

Text

Carfilzomib Market Overview and Regional Outlook Study 2024 – 2034

Carfilzomib Market Defination:

TheCarfilzomib Market refers to the economic and clinical landscape surrounding the pharmaceutical drug carfilzomib. Carfilzomib is a proteasome inhibitor used primarily in the treatment of multiple myeloma, a type of cancer affecting plasma cells in bone marrow. It functions by selectively inhibiting the proteasome, a complex protein-degrading machinery essential for cell function and survival. This inhibition leads to the accumulation of proteins within cancer cells, triggering cell death through apoptosis.

Print This Guide for Future Reference:https://wemarketresearch.com/reports/request-free-sample-pdf/carfilzomib-market/1493

Exploring the Carfilzomib Market: Advancements in Multiple Myeloma Treatment

In the realm of oncology, particularly in the treatment landscape of multiple myeloma, carfilzomib has emerged as a cornerstone therapy, offering new hope and improved outcomes for patients. This blog delves into the dynamic carfilzomib market, examining its impact, current trends, challenges, and future prospects.

Understanding Carfilzomib

Carfilzomib is a proteasome inhibitor approved for the treatment of relapsed or refractory multiple myeloma. It works by selectively and irreversibly binding to the 20S proteasome, disrupting protein degradation in cancer cells and inducing apoptosis. Approved by the FDA in 2012, carfilzomib has since been integrated into treatment protocols, often in combination with other agents like lenalidomide and dexamethasone.

Market Dynamics

Current Landscape: The Carfilzomib Market is driven by its efficacy in treating relapsed or refractory multiple myeloma, particularly in patients who have received prior therapies. Its mechanism of action and clinical benefits have positioned it as a valuable option in the treatment algorithm for multiple myeloma.

Treatment Advancements: Clinical studies have demonstrated that carfilzomib-based regimens prolong progression-free survival and overall survival compared to traditional therapies. Its approval marked a significant advancement in the management of multiple myeloma, offering a targeted approach to combating the disease.

Competitive Environment: Within the proteasome inhibitor class, carfilzomib competes with bortezomib and ixazomib, each offering unique profiles in terms of efficacy, safety, and administration convenience. Ongoing research aims to optimize carfilzomib’s use through novel combinations and sequencing strategies to maximize patient benefit.

Clinical Applications

Approved Indications: Carfilzomib is primarily indicated for use in combination with other agents for the treatment of relapsed or refractory multiple myeloma. Clinical trials are also exploring its potential in newly diagnosed patients and maintenance therapy settings, broadening its scope of application.

Future Directions: Research efforts are focused on expanding carfilzomib’s indications and understanding its synergies with emerging therapies such as immunomodulators, monoclonal antibodies, and cellular therapies like CAR-T cells. These endeavors aim to further improve treatment outcomes and offer personalized therapeutic approaches.

Carfilzomib Market Challenges and Opportunities

Challenges: Economic considerations remain a significant challenge in the adoption of carfilzomib, given its high cost as a biologic therapy. Managing treatment-related adverse events, such as cardiovascular complications and hematologic toxicities, also requires vigilant monitoring and proactive management strategies.

Opportunities: Advances in biomarker identification and personalized medicine offer opportunities to tailor carfilzomib-based therapies to individual patient profiles. Moreover, ongoing research into combination therapies and novel formulations aims to enhance efficacy while minimizing adverse effects, thereby improving patient adherence and outcomes.

Patient Impact and Healthcare Considerations

Patient Experience: For patients diagnosed with relapsed or refractory multiple myeloma, carfilzomib represents a crucial treatment option that can potentially extend survival and improve quality of life. Education and support programs play a vital role in helping patients manage treatment-related challenges and adhere to therapy.

Healthcare System Implications: Integrating carfilzomib into clinical practice requires healthcare providers to navigate complex treatment algorithms and ensure appropriate patient monitoring. Collaboration among multidisciplinary teams, including oncologists, hematologists, and supportive care specialists, is essential for optimizing patient care and outcomes.

Regulatory and Market Access

Regulatory Landscape: Regulatory approvals and reimbursement policies influence the accessibility of cCarfilzomib Market in different regions. Streamlining regulatory processes and demonstrating cost-effectiveness through real-world evidence are crucial for enhancing market access and patient affordability.

Market Expansion: As clinical data continues to evolve and new indications are explored, the carfilzomib market is poised for growth. Market expansion strategies should prioritize evidence-based medicine and stakeholder collaboration to drive adoption and improve patient access.

Conclusion

In conclusion, the carfilzomib market represents a significant advancement in the treatment of multiple myeloma, reflecting the transformative impact of targeted therapies in oncology. Its approval and integration into treatment protocols underscore a shift towards personalized medicine and multidisciplinary care approaches that optimize patient outcomes.

While challenges such as economic considerations and treatment-related adverse events persist, ongoing research and collaborative efforts among stakeholders are paving the way for continued innovation and improvement inCarfilzomib-Based Therapies. By addressing these challenges proactively, healthcare providers and pharmaceutical companies can ensure that carfilzomib realizes its full potential in improving the lives of patients battling multiple myeloma.

Stay informed and engaged with the latest developments in the carfilzomib market to contribute to advancements in oncology and patient-centered care.

0 notes

cancersfakianakis1 · 7 years ago

Text

The European Medicines Agency Review of Carfilzomib for the Treatment of Adult Patients with Multiple Myeloma Who Have Received at Least One Prior Therapy

AbstractOn November 19, 2015, a marketing authorization valid through the European Union was issued for carfilzomib in combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma (MM) who have received at least one prior therapy.In a phase III trial in patients with relapsed MM, median progression‐free survival (PFS) for patients treated with carfilzomib in combination with lenalidomide and dexamethasone (CRd) was 26.3 months versus 17.6 months for those receiving lenalidomide and dexamethasone alone (hazard ratio = 0.69; 95% confidence interval, 0.57–0.83; one‐sided log‐rank p value < .0001). The most frequently observed toxicity (grade ≥3, treatment arm vs. control arm) in the phase III trial included neutropenia (29.6% vs. 26.5%), anemia (17.9% vs. 17.7%), thrombocytopenia (16.8% vs. 12.3%), pneumonia (12.5% vs. 10.5%), fatigue (7.7% vs. 6.4%), hypertension (4.6% vs. 2.1%), diarrhea (3.8% vs. 4.1%), and respiratory tract infection (4.1% vs. 2.1%).The objective of this article is to summarize the scientific review of the application leading to regulatory approval in the European Union. The scientific review concluded that the gain in PFS of 8.7 months observed with the combination of CRd was considered clinically meaningful and was supported by a clear trend in overall survival benefit, although the data were not mature. The delay in disease progression appeared superior to available alternatives in the setting of relapsed MM at the time of the marketing authorization of carfilzomib. Therefore, given the overall accepted safety profile, which was considered manageable in the current context, the benefit risk for CRd was considered positive.Implications for Practice.Carfilzomib (Kyprolis) was approved in the European Union in combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. The addition of carfilzomib to lenalidomide and dexamethasone resulted in a clinically meaningful and statistically significant improvement of progression‐free survival compared with lenalidomide and dexamethasone, which was supported by a clear trend in overall survival benefit, although the data were not mature. At the time of the marketing authorization of carfilzomib, the delay in disease progression appeared superior to available alternatives in the setting of relapsed multiple myeloma. In terms of safety, the overall accepted safety profile was considered manageable. http://ift.tt/2jgrDrL

#Oncology-Sfakianakis

0 notes